Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|March 10, 2025
Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative AnalysisMilou A Hogervorst, Rick A Vreman, Theresa A Oduol, et al.
Health Policy (Amsterdam, Netherlands)|July 17, 2023
Systemic anticancer treatment in the Netherlands: Few hospitals treat many patients, many hospitals treat few patientsNiels W L Peeters, Rick A Vreman, Geert A Cirkel, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 6, 2020
A novel method for predicting the budget impact of innovative medicines: validation study for oncolyticsJoost W Geenen, Svetlana V Belitser, Rick A Vreman, et al.
International Journal of Technology Assessment in Health Care|June 15, 2023
The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessmentsRick A Vreman, Daan van Hoof, Anna Nachtnebel, et al.
Clinical Pharmacology and Therapeutics|April 3, 2020
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and EuropeRick A Vreman, Huseyin Naci, Wim G Goettsch, et al.
Clinical Pharmacology and Therapeutics|October 10, 2018
Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved DrugsRick A Vreman, Jacoline C Bouvy, Lourens T Bloem, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 16, 2023
Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countriesZoltán Kaló, Maciej Niewada, Tamás Bereczky, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 20, 2022
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndromeWout W A van den Broek, Jacqueline G van Paassen, Marieke E Gimbel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 13, 2021
Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse ScenariosThomas F Broekhoff, Carly C G Sweegers, Eline M Krijkamp, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2024
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)Marcelien H E Callenbach, Daphne Schoenmakers, Rick A Vreman, et al.
Pageof 5